- Home
- LICY vs HLVX Comparison
LICY vs HLVX Comparison
Compare LICY & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICY
- HLVX
- Stock Information
- Founded
- LICY 2016
- HLVX 2020
- Country
- LICY Canada
- HLVX United States
- Employees
- LICY N/A
- HLVX N/A
- Industry
- LICY Environmental Services
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- LICY Industrials
- HLVX Health Care
- Exchange
- LICY Nasdaq
- HLVX Nasdaq
- Market Cap
- LICY 83.8M
- HLVX 87.6M
- IPO Year
- LICY N/A
- HLVX 2022
- Fundamental
- Price
- LICY $2.41
- HLVX $1.89
- Analyst Decision
- LICY Hold
- HLVX Hold
- Analyst Count
- LICY 3
- HLVX 5
- Target Price
- LICY $5.36
- HLVX $2.33
- AVG Volume (30 Days)
- LICY 2.3M
- HLVX 124.1K
- Earning Date
- LICY 11-07-2024
- HLVX 11-07-2024
- Dividend Yield
- LICY N/A
- HLVX N/A
- EPS Growth
- LICY N/A
- HLVX N/A
- EPS
- LICY N/A
- HLVX N/A
- Revenue
- LICY $27,400,000.00
- HLVX N/A
- Revenue This Year
- LICY $48.13
- HLVX N/A
- Revenue Next Year
- LICY $18.15
- HLVX N/A
- P/E Ratio
- LICY N/A
- HLVX N/A
- Revenue Growth
- LICY N/A
- HLVX N/A
- 52 Week Low
- LICY $1.22
- HLVX $1.55
- 52 Week High
- LICY $15.36
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- LICY 46.18
- HLVX 50.42
- Support Level
- LICY $2.69
- HLVX $1.80
- Resistance Level
- LICY $4.98
- HLVX $2.02
- Average True Range (ATR)
- LICY 0.57
- HLVX 0.08
- MACD
- LICY -0.04
- HLVX 0.01
- Stochastic Oscillator
- LICY 13.60
- HLVX 41.86
About LICY Li-Cycle Holdings Corp.
Li-Cycle Holdings Corp is a lithium-ion battery resource recovery and lithium-ion battery recycler. The company's proprietary process Spoke and Hub recycling process is designed at its Spokes, to process battery manufacturing scrap and end-of-life batteries to produce black mass and other intermediate products, and at its Hubs, to process black mass to recover raw materials, including but not limited to lithium carbonate, cobalt sulphate, and nickel sulphate.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.